Spyre Therapeutics, Inc. (SYRE) Tops Q3 EPS by 62c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($0.15), $0.62 better than the analyst estimate of ($0.77).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Popular stocks with increasing option volume: SPCX MU INTC NFLX PLTR SOFI MSTR AMC IBM SMCI HOOD
• Varonis Systems (VRNS) call put ratio 4.4 calls to 1 put with a focus on July 35, 40 and 45 calls as share price up 6.4%